SMS Pharma Surges on 21% Revenue Growth, Margin Boost from Integration

OTHER
Whalesbook Logo
AuthorRiya Kapoor|Published at:
SMS Pharma Surges on 21% Revenue Growth, Margin Boost from Integration
Overview

SMS Pharmaceuticals Ltd. posted robust Q3 FY26 results, with revenue surging 21% year-over-year to ₹210.45 crore and Profit After Tax (PAT) growing 29% YoY to ₹23.47 crore. EBITDA also saw a significant 31% jump. The company highlighted strong demand, market share gains, and the positive impact of its backward integration initiative, which helped sustain margin resilience despite a year-on-year dip in gross margins. The company is progressing with its ₹280 crore capacity expansion and remains on track for ~20% revenue growth in FY26.

📉 The Financial Deep Dive

SMS Pharmaceuticals Limited has reported a strong financial performance for the third quarter (Q3) and nine months (9M) ended December 31, 2025. The company showcased significant year-over-year (YoY) growth across key metrics, driven by volume expansion and operational efficiencies.

The Numbers:

  • Q3 FY26 Performance:

    • Revenue: ₹210.45 crore, a substantial 21% increase YoY.
    • EBITDA: ₹43.65 crore, up 31% YoY.
    • EBITDA Margin: 21%, an improvement of 158 basis points (bps) YoY.
    • Profit After Tax (PAT): ₹23.47 crore, marking a 29% increase YoY.
    • PAT Margin: 11%, up 63 bps YoY.
    • Earnings Per Share (EPS): ₹2.59, a 20% increase YoY.

  • 9M FY26 Performance:

    • Revenue: ₹648.92 crore, up 21% YoY.
    • EBITDA: ₹131.38 crore, up 34% YoY.
    • EBITDA Margin: 20%, an improvement of 188 bps YoY.
    • PAT: ₹69.27 crore, an impressive 42% increase YoY.
    • PAT Margin: 11%, up 154 bps YoY.
    • EPS: ₹7.64, a 32% increase YoY.

The Quality & Strategy:

While overall profitability metrics show strong growth, a deeper look reveals a mixed picture for gross margins. Gross margins in Q3 FY26 stood at 36%, a year-on-year decline of 313 bps. However, management indicated that these improved sequentially (QoQ) due to the full-quarter impact of the backward integration project commissioned in Q1 FY26. This strategic initiative is crucial for sustaining margin resilience and strengthening the company's competitive position, especially in regulated markets like the US. The company also reported achieving its full-year target of 10 Drug Master File (DMF)/Certificate of Suitability (CEP) filings ahead of schedule and aims for approximately 20 submissions in the next two years.

Risks & Outlook:

The primary risk highlighted is the year-on-year compression in gross margins, although the sequential improvement and management's commentary on backward integration suggest this is being actively addressed. Execution risks associated with the ongoing ₹280 crore capacity expansion program, scheduled for completion by FY27, will also need monitoring.

The outlook remains positive, with management confidently projecting approximately 20% revenue growth for FY26 and EBITDA margins expected to stay above 20%. Growth drivers include continued benefits from backward integration, strong R&D capabilities, advanced manufacturing infrastructure, a diversified product portfolio, and anticipated price stabilization in key APIs. The company's broad customer base across over 70 countries diversifies geographical risk.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.